Insider Selling: Health Catalyst, Inc. (NASDAQ:HCAT) Insider Sells $50,762.96 in Stock

Health Catalyst, Inc. (NASDAQ:HCAT) insider Linda Llewelyn sold 6,442 shares of the stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $7.88, for a total transaction of $50,762.96. Following the completion of the transaction, the insider now directly owns 98,702 shares of the company’s stock, valued at approximately $777,771.76. The trade was a 6.13 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Linda Llewelyn also recently made the following trade(s):

• On Tuesday, October 15th, Linda Llewelyn sold 1,324 shares of Health Catalyst stock. The stock was sold at an average price of $8.16, for a total transaction of $10,803.84.

Health Catalyst Stock Performance

NASDAQ:HCAT opened at $7.09 on Friday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.41 and a quick ratio of 1.41. Health Catalyst, Inc. has a 1 year low of $5.42 and a 1 year high of $11.41. The stock’s 50 day simple moving average is $8.11 and its two-hundred day simple moving average is $7.45. The company has a market cap of $431.41 million, a price-to-earnings ratio of -5.25 and a beta of 1.31.

Health Catalyst (NASDAQ:HCAT) last posted its quarterly earnings results on Wednesday, November 6th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.03). The company had revenue of $76.40 million during the quarter, compared to analysts’ expectations of $76.27 million. Health Catalyst had a negative return on equity of 7.51% and a negative net margin of 26.20%. The company’s quarterly revenue was up 3.5% on a year-over-year basis. During the same period in the prior year, the business earned ($0.22) EPS. As a group, equities analysts anticipate that Health Catalyst, Inc. will post -0.33 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have commented on the stock. Evercore ISI raised their price target on shares of Health Catalyst from $8.00 to $10.00 and gave the stock an “outperform” rating in a report on Tuesday, October 8th. Royal Bank of Canada upped their price target on Health Catalyst from $8.00 to $9.00 and gave the company a “sector perform” rating in a research report on Thursday, November 7th. JPMorgan Chase & Co. boosted their target price on shares of Health Catalyst from $10.00 to $13.00 and gave the company an “overweight” rating in a report on Wednesday, September 4th. Stephens boosted their price objective on shares of Health Catalyst from $7.00 to $9.00 and gave the company an “equal weight” rating in a research note on Thursday, November 14th. Finally, Citigroup boosted their price target on shares of Health Catalyst from $9.00 to $10.50 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Three research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, Health Catalyst has a consensus rating of “Moderate Buy” and a consensus target price of $11.79.

Institutional Trading of Health Catalyst

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. First Light Asset Management LLC grew its holdings in Health Catalyst by 438.5% in the 2nd quarter. First Light Asset Management LLC now owns 3,956,089 shares of the company’s stock valued at $25,279,000 after buying an additional 3,221,408 shares in the last quarter. Millennium Management LLC grew its holdings in shares of Health Catalyst by 96.3% during the second quarter. Millennium Management LLC now owns 2,413,280 shares of the company’s stock worth $15,421,000 after buying an additional 1,184,131 shares during the last quarter. Nepsis Inc. lifted its position in Health Catalyst by 67.9% in the third quarter. Nepsis Inc. now owns 2,104,528 shares of the company’s stock valued at $17,131,000 after purchasing an additional 851,448 shares during the period. Fred Alger Management LLC purchased a new stake in Health Catalyst during the third quarter worth about $6,858,000. Finally, Portolan Capital Management LLC acquired a new position in Health Catalyst during the third quarter worth about $5,402,000. Institutional investors and hedge funds own 85.00% of the company’s stock.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.